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Abstract
Background: Colonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent
studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the
colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum,
ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could
increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the
right-sided “blind spot”.
Methods: We previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a
patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the
detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I,
65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12;
unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples
were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%);
regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population.
Results: The panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall
sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with
left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95).
Conclusion: This seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a
sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for
a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance
of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to
enhanced CRC screening effectiveness.
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Background
Colorectal cancer (CRC) is the third most common cancer
and the second most common cause of cancer deaths in
the United States and Canada. The disease is expected to
be diagnosed in approximately 142,820 Americans in
2013, and an estimated 50,830 people are expected to die
of CRC in that year [1]. In Canada an estimated 23,900
Canadians will be diagnosed with CRC in 2013, and 9,200
Canadians will die of the disease [2].
In the National Polyp Study, colonoscopy with adenoma
removal was associated with a reduction in CRC as high
as 90% [3]. Recently, however, several reports have
questioned whether colonoscopy as practiced in the com-
munity reduces CRC and mortality to the same degree as
that reported by highly specialized cancer centers [4-7].
Studies have found that although colonoscopy effective-
ness is high for lesions that arise on the left side of the
colon, the procedure fails to confer similar levels of
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sided lesions. In 2009, a case–control study of colonoscopy
in Ontario, Canada, reported that although the procedure
reduced mortality from left-sided lesions by about 40%, no
reduction in deaths was evident when CRC originated in
the right colon [4]. Similarly, in a population-based retro-
spective analysis from Manitoba, colonoscopy found no
reduction in CRC mortality in the case of proximal lesions
[5]. A large German, statewide cross-sectional study of col-
onoscopy found the prevalence of advanced colorectal
neoplasms strongly reduced by 67% in left-sided lesions,
but this protection did not extend when the lesions were
right-sided [6]. A later study by the same authors, which
emphasized high-quality colonoscopy, found the procedure
to be associated with a reduced risk of 56% for right
colonic lesions, which is an improvement over earlier
reports, but is less than the 84% reduced risk for CRC the
authors observed for left colonic lesions [7].
A number of suggestions have been advanced to ex-
plain why colonoscopy may be less effective in the right
colon than in the left. The technology is operator-
dependent and requires complete endoscopic evaluation,
which is more difficult to complete in the right side of
the colon. Bowel cleansing and preparation for colonos-
copy may be less adequate on the right side, making le-
sions more difficult to visualize. Nonpolypoid flat or
depressed lesions are more prevalent in the right than in
the left side of the colon, and these are more challenging
to identify and remove [8]. There may also be differences
in biology between proximal and distal lesions; for ex-
ample, distal and proximal CRCs show genetic and mo-
lecular differences [9].
We previously reported a seven-gene, blood-based bio-
marker panel for CRC detection [10]. For this current
study, we hypothesize that this gene panel, which is a
blood-based test, not dependent on localization, prepar-
ation or operator technique, can provide a non-biased
method for detecting CRC arising in either the right or
the left side of the colon.
The test is intended as a pre-screening tool and conveni-
ent companion diagnostic test to help those patients who
are averse to colonoscopy and to the fecal occult blood
test to make an informed decision based on their individ-
ual molecular profile. Because of its narrow focus, the test
is not expected to alter clinical practice for patients who
comply with recommended screening schedules.
Methods
Sample collection procedures and details of method-
ology for identification of the seven-gene blood-based
biomarker panel for CRC were reported in our earlier
study [10]. Briefly, 9,199 blood samples were taken from
screening colonoscopy subjects at twenty-four centers
located in the Greater Toronto Area and surrounding
regions and in the United States, between March 2005
and March 2008. Uniformity of collection procedures at
the different sites was ensured by the use of identical
study protocols, uniform training of personnel, and peri-
odic site monitoring. Informed consent was obtained
according to protocols approved by the Research Ethics
Board of each of the participating twenty-four clinics
and hospitals.
The low incidence of CRC in the colonoscopy screen-
ing population made it necessary to recruit additional
patients from cancer clinics in Toronto. In these cases,
blood samples were collected prior to any treatment, in-
cluding surgery. Patients enrolled in colonoscopy clinics
provided blood prior to colonoscopy. Samples were cate-
gorized following review of pathology reports.
Case samples comprised blood samples taken from
colonoscopy-confirmed CRC patients who had not under-
gone CRC treatment. Institutional pathologists determined
cancer stage according to the American Joint Committee
on Cancer (AJCC) Tumour, Node, and Metastases (TNM)
staging system [11]. Controls comprised samples from sub-
jects with no pathology at colonoscopy.
The qRT-PCR training set was composed of 112 well-
characterized CRC and 120 control samples (total=232)
taken from the population described above. Cancer and
control samples were matched for age, sex, body mass
index (BMI) and ethnicity.
An independent blind test set was composed of 410
average-risk subjects following colonoscopy (202 CRC/
208 control). Average risk was defined as follows: sub-
jects aged ≥ 50 with no cancer or chemotherapy history,
no previous record of colorectal disease (adenomatous
polyps, CRC or inflammatory bowel disease) and no
first-degree relatives with CRC. Cancer and control sam-
ples were matched for sex, BMI and ethnicity. The aver-
age age of patients was 3.6 years older than that of
control subjects.
Most of the patients and controls who provided samples
for qRT-PCR experiments had one or multiple co-
morbidities, most commonly, hypertension, hypercholes-
terolemia, diabetes, arthritis, anemia and allergies. More
than 56% of the CRC samples were diagnosed with early
stage I and II CRC and 32% with stage III cancer. (Table 1)
This means that approximately 90% of cases were poten-
tially treatable CRC patients, which increases the practical
value of the test.
Blood collection and RNA isolation
Samples were collected in PAXgene™ tubes (PreAnalytiX)
and processed according to the manufacturer’sB l o o d
RNA Kit protocol. RNA quality for all samples was
assessed using a 2100 Bioanalyzer RNA 6000 Nano Chip
(Agilent Technologies). All samples met quality criteria:
RIN≥7.0; 28S:18S rRNA ratio≥1.0 and a validated
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by absorbance at 260nm in a DU-640 Spectrophotometer
(Beckman Coulter).
Quantitative reverse-transcriptase polymerase chain reaction
One microgram of RNA was reverse-transcribed into single-
stranded complementary DNA (cDNA) using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) in a
20μL reaction. For PCR, 20ng cDNA was mixed with
QuantiTect® Probe PCR Master Mix (Qiagen), and TaqMan®
dual-labeled probe and primers corresponding to the gene
of interest and reference gene, in a 25 μL reaction volume.
PCR amplification was performed using a 7500 Real-Time
PCR System (Applied Biosystems). Each sample was tested
in duplicate reactions on the same PCR plate. The run re-
sults were subjected to quality control processes, and failed
samples were repeated. Samples that failed a second time
were excluded from the analysis.
For the blind test set, first, we selected samples with
disease status known (in order to balance the sample
groups and avoid biases in clinical and demographic
characteristics). Selected samples were then randomized
and assigned blinded identification prior to the experi-
ment, and data analysis was performed by scientists
blinded to the disease status.
The seven-gene panel
Details of the characterization and validation of the seven-
gene panel to identify CRC have been described previously
[10]. In that study a seven-gene panel (ANXA3, CLEC4D,
LMNB1, PRRG4, TNFAIP6, VNN1, IL2RB)d i s c r i m i n a -
ted CRC in the training set [area under the receiver-
operating-characteristic curve (AUC ROC), 0.80; accuracy,
73%; sensitivity, 82%; specificity 64%]. The independent
blind test set confirmed performance (AUC ROC, 0.80;
accuracy, 71%; sensitivity, 72%; specificity, 70%).
For the present study we re-analyze the previously
reported data in order to determine the ability of the seven
gene panel not only to identify the presence of CRC but
also to identify cancer stages and left- and right-sided
colon cancer.
Results
The training set data was used to determine the best coef-
ficients for a logistic regression model using 6 ratios of the
7 genes most discriminative for CRC. This model was then
used to predict the CRC risk for the test set samples.
Breaking the data down by cancer stages, we were able
to find the same predictive values for left- and right-
sided cancers as for CRC detection as in the original
paper (Table 2).
In this study, CRC detection sensitivity was generally
higher for right-sided cancer except in the case of TNM
stage I in the test set. However, this finding may be sim-
ply a sampling issue. To resolve this question, we com-
bined all training and test set samples and performed
2-fold cross validation, iterated 1000 times. This process
partitions the samples into 2 halves such that that the
coefficients of the model are fitted to the training half
and applied to the test half.
The results for all the test halves after 1000 permuta-
tions represent a less biased estimate of the performance
of the gene panel. As expected, the lower sensitivity for
right-sided TNM I as compared with left-sided TNM I
cancers is no longer observed in the cross-validated
results. Overall, right-sided lesions are detected at a higher
sensitivity than left-sided lesions; however, there are fewer
right-sided samples, so the observed higher sensitivity
may not be statistically significant. As can be seen from
the box and whisker plots of the distribution of the
prediction scores, the 98% confidence intervals show con-
siderable overlap both across all TNM stages and for left
and right sided cancers (Figure 1).
The panel detected left-sided (75%, 156/208) and right-
sided (85%, 92/108) lesions with an overall sensitivity of
Table 2 Correct call rate
Training Test 1000X 2-Fold
Cross validation
Stage Left Right Left Right Left Right
TNM I
63% 92% 61% 44% 67% 66%
(12/19) (11/12) (28/46) (7/16) (43.5/65) (18.6/28)
TNM II
70% 91% 81% 89% 79% 89%
(14/20) (10/11) (30/37) (16/18) (45.0/57) (25.9/29)
TNM III
86% 100% 74% 84% 83% 90%
(18/21) (13/13) (29/39) (21/25) (49.6/60) (34.3/38)
TNM IV
86% 100% 50% 100% 66% 100%
(6/7) (5/5) (5/10) (7/7) (11.2/17) (12.0/12)
Unknown
80% 100% 100% n/a 80% 100%
(4/5) (1/1) (4/4) (0/0) (7.2/9) (1.0/1)
All Stages
75% 95% 71% 77% 75% 85%
(54/72) (40/42) (96/136) (51/66) (156.5/208) (91.8/108)
Control 64% (77/120) 70% (145/208) 64% (210/328)
Table 1 Available samples
Sample # Training Test Combined
Category Left Right Left Right Left Right
T N M I 1 91 24 61 66 52 8
TNM II 20 11 37 18 57 29
TNM III 21 13 39 25 60 38
TNM IV 7 5 10 7 17 12
Unknown 5 1 4 0 9 1
All Stages 72 42 136 66 208 108
Control 120 208 328
NB Two training samples have both left and right cancer.
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cancer (stages I to III) was detected with a left-sided lesion
sensitivity of 76% (138/182) and a right-sided sensitivity of
83% (79/95).
Discussion
In several studies we have shown that gene signatures
obtained using blood mRNA can identify a variety of
conditions occurring in various sites throughout the
body, including heart failure [12], inflammatory bowel
disease [13,14], psychiatric disorders [15-17] and various
cancers [10,18-20]. These studies suggest that blood cells
may act as “sentinels” that can mirror health or disease
anywhere in the body. Blood transcriptomic signatures
thus reflect molecular changes regardless of where they
occur in the body.
We have also recently reported a blood test based on
the performance characteristics of a seven-gene panel
that enables us to assess a patient’s current risk of hav-
ing CRC [10]. As a blood test similar to other routine
blood tests, the assay overcomes a number of reported
limitations to patient acceptance of CRC screening
using currently utilized tests. Such barriers include
patients’ fear of pain, inconvenience, unpleasantness,
pre-procedure colon evacuation methods, the need to
take time off work and to be sedated, risks such as
bowel perforation, bleeding and other complications
(for colonoscopy and other endoscopic methods) and
patient embarrassment and beliefs that methods are
unsanitary, unpleasant or inconvenient (fecal tests)
[21-27]. By contrast, a simple, convenient blood test
should encourage increased compliance with screening
recommendations.
In this study we use the same seven-gene panel to ad-
dress another issue limiting the effectiveness of colonos-
copy: the right-sided bias observed in such technology.
Figure 2 Prediction sensitivity for all CRC at each stage. Figures inside the bars show the ratios of average positive calls from 1000 iterations
of 2-fold cross validation analysis.
Figure 1 Distribution of prediction scores from 1000 iterations of 2-fold cross-validation analysis. Boxes indicate the central 50 percentile
with whiskers showing the extent of the 98 percentile.
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left, distal colon. The former includes the cecum, ascend-
ing colon, hepatic flexure and transverse colon, and the
latter the descending and sigmoid colon and rectum. Col-
onoscopy tends to bias towards detection on the left side,
for reasons both technical and biological. The blood-based
test for CRC reported in this study would have the effect
of reducing such bias, thus potentially increasing detection
rates for right sided lesions.
This pre-screening test is mainly intended for detec-
tion of TNM I to TNM III patients. For these patients,
test sensitivity is 76% for left-sided cancers and 84% for
right-sided cancers. TNM IV stage patients are likely to
be diagnosed by conventional means and are less likely
to benefit much from intervention.
Conclusion
This study finds that detection of CRCs using mRNA
biomarkers from whole blood is equally sensitive to
treatable TNM I – III lesions located throughout the
colon (Figure 2). These findings support the use of the
seven-gene panel as a non-biased method for CRC de-
tection for both left and right-sided lesions.
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